==============================================================================

                                UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                     ----------------------------------

                                  FORM 8-K


                               CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(d) OF
                     THE SECURITIES EXCHANGE ACT OF 1934


                        Commission File Number 1-9601


    Date of Report (date of earliest event reported): September 12, 2006


                         K-V PHARMACEUTICAL COMPANY
           (Exact name of registrant as specified in its charter)


              DELAWARE                                  43-0618919
   (State or other jurisdiction of         (I.R.S. Employer Identification No.)
   incorporation or organization)

        2503 SOUTH HANLEY ROAD
         ST. LOUIS, MISSOURI                               63144
 (Address of principal executive offices)                (Zip Code)



                               (314) 645-6600
            (Registrant's telephone number, including area code)

         Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:

  / / Written communications pursuant to Rule 425 under the Securities Act.
  / / Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  / / Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act.
  / / Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act.

==============================================================================







                          SECTION 7 - REGULATION FD

ITEM 7.01         REGULATION FD DISCLOSURE

                  Attached and incorporated herein by reference as Exhibit
99 is a press release issued by K-V Pharmaceutical Company (the "Company")
announcing that it has received notification of approval from the United
States Food and Drug Administration to market six dosages of a product. The
information in this Form 8-K, including Exhibit 99 attached hereto, is being
furnished under Regulation FD and shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended. The
Company has posted this Form 8-K on its internet website at
www.kvpharmaceutical.com. A copy of the press release is attached hereto as
Exhibit 99.

                                    * * *

                                     -2-







                                 SIGNATURES


                  Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.


Dated:  September 12, 2006

                                K-V PHARMACEUTICAL COMPANY


                                By:  /s/ Richard H. Chibnall
                                   -------------------------
                                     Richard H. Chibnall
                                     Vice President, Finance



                                     -3-